NCT06633497
Evaluating the Role of the Microbiome in Antidepressant Treatment in Adolescents.
StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor Secondary endpoints: details revised at 1 of 4 entriesv2
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Gut microbiome composition
Timeframe: Stool samples will be collected at enrollment (baseline), then following enrollment: daily for the first 7 days and biweekly at weeks 2, 4, 6, and 8.
Efficacy of fluoxetine to treat depression symptoms in adolescents
Timeframe: The CDRS-R will be administered at baseline and week 6.
Secondary (4)
Efficacy of fluoxetine to improve self-reported depression symptoms in adolescents
Efficacy of fluoxetine to treat anxiety symptoms in adolescents
Pharmacogenetic (PGx) metabolizer status
Steady-state plasma concentrations of fluoxetine
Sites
1 site in 1 country
- Rady Children's Hospital San DiegoSan Diego, California, United States